United Statesfireflybiologics.com
Firefly Bio, Inc. is a biotechnology company headquartered in South San Francisco, California. It develops degrader antibody conjugates (DACs) via its proprietary Firelink platform, which targets selective protein degradation in tumor cells for KRAS-driven and other solid cancers.
On June 8, 2026, Johnson & Johnson announced a definitive agreement to acquire the company for $1 billion in cash, subject to regulatory approvals, with closing expected later in 2026.
Also known as Firefly Bio Inc. and Firefly Biologics.
None yet. When a new project in the record names Firefly Bio as owner, partner or investor, it shows here.
Adds Firelink™ degrader antibody conjugate platform to target pan‑KRAS and other hard‑to‑treat solid tumors; transaction carries near‑term R&D charge and EPS dilution.
Quarterly sales topped $25.3B; adjusted net earnings and EPS rose, free cash flow improved, and full-year revenue guidance was raised above $100B for the first time.
Targets KRAS-driven solid tumours with a selective protein degrader; closing expected later this year pending regulatory approvals.
